Search Results - "Rothenstein, Jeffrey"

Company Stock Prices Before and After Public Announcements Related to Oncology Drugs by Rothenstein, Jeffrey M., Tomlinson, George, Tannock, Ian F., Detsky, Allan S.

“…Background Phase III clinical trials and Food and Drug Administration (FDA) regulatory decisions are critical for success of new drugs and can influence a…”
Get full text

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program by Illini, Oliver, Hochmair, Maximilian Johannes, Fabikan, Hannah, Weinlinger, Christoph, Tufman, Amanda, Swalduz, Aurélie, Lamberg, Kristina, Hashemi, Sayed M. S., Huemer, Florian, Vikström, Anders, Wermke, Martin, Absenger, Gudrun, Addeo, Alfredo, Banerji, Shantanu, Calles, Antonio, Clarke, Stephen, Di Maio, Massimo, Durand, Alice, Duruisseaux, Michaël, Itchins, Malinda, Kääränien, Okko-Sakari, Krenn, Florian, Laack, Eckart, de Langen, Adrianus Johannes, Mohorcic, Katja, Pall, Georg, Passaro, Antonio, Prager, Gerald, Rittmeyer, Achim, Rothenstein, Jeffrey, Schumacher, Michael, Wöll, Ewald, Valipour, Arschang

“…Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such…”
Get full text

The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report by Chen, Kaitlin H., Barnes, Tristan A., Laskin, Janessa, Cheema, Parneet, Liu, Geoffrey, Iqbal, Mussawar, Rothenstein, Jeffrey, Burkes, Ronald, Tsao, Ming-Sound, Leighl, Natasha B.

“…Liquid biopsy is recommended to diagnose molecular resistance to targeted therapy in patients with lung cancer. Nevertheless, not all jurisdictions provide…”
Get full text

Cloning of Transforming Growth Factor-β1 (TGF-β1) and Its Type II Receptor from Zebrafish Ovary and Role of TGF-β1 in Oocyte Maturation by Kohli, Gurneet, Hu, Siqin, Clelland, Eric, Di Muccio, Tamara, Rothenstein, Jeffrey, Peng, Chun

“…TGF-β is a multifunctional factor involved in regulating a variety of cellular activities. In mammals, TGF-β is known to regulate reproduction, including…”
Get full text

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH) by Peters, Solange, Gettinger, Scott, Johnson, Melissa L, Jänne, Pasi A, Garassino, Marina C, Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A, Chaft, Jamie E, Carcereny Costa, Enric, Patel, Jyoti D, Chow, Laura Q M, Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A, Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta

“…Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced…”
Get full text

Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest by Donovan, Jeffrey C H, Rothenstein, Jeffrey M, Slingerland, Joyce M

“…Transforming growth factor beta (TGF-beta) induces G(1) arrest in susceptible cells by multiple mechanisms that inhibit the G(1) cyclin-dependent kinases…”
Get full text

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer by Reck, Martin, Wehler, Thomas, Orlandi, Francisco, Nogami, Naoyuki, Barone, Carlo, Moro-Sibilot, Denis, Shtivelband, Mikhail, González Larriba, Jose Luis, Rothenstein, Jeffrey, Früh, Martin, Yu, Wei, Deng, Yu, Coleman, Shelley, Shankar, Geetha, Patel, Hina, Kelsch, Claudia, Lee, Anthony, Piault, Elisabeth, Socinski, Mark A

“…Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in…”
Get full text

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT) by Breadner, Daniel Adam, Vincent, Mark David, Liu, Geoffrey, Rothenstein, Jeffrey, Menjak, Ines B., Cheema, Parneet Kaur, Juergens, Rosalyn A., Mithoowani, Hamid, Bains, Puneet, Wang, Ying, Wheatley-Price, Paul

“…TPS9160 Background: The results of the FLAURA study established osimertinib as the new first-line standard of care for patients with the two ‘common’ types of…”
Get full text

ALK inhibitors, resistance development, clinical trials by Rothenstein, J M, Chooback, N

“…The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of…”
Get full text

Managing treatment-related adverse events associated with Alk inhibitors by Rothenstein, J M, Letarte, N

“…Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs)…”
Get full text

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219 by Melosky, Barbara, Bradbury, Penelope, Tu, Dongsheng, Florescu, Marie, Reiman, Anthony, Nicholas, Garth, Basappa, Naveen, Rothenstein, Jeffrey, Goffin, John R., Laurie, Scott A., Wheatley-Price, Paul, Leighl, Natasha, Goss, Glenwood, Reaume, M. Neil, Butts, Charles, Murray, Nevin, Card, Cynthia, Ko, Jenny, Blais, Normand, Gray, Samantha, Lui, Hongbo, Brown-Walker, Pamela, Kaurah, Pardeep, Prentice, Leah M., Seymour, Lesley

“…•No difference in efficacy/toxicity for intermittent or continuous selumetinib.•Combination of selumetinib and platinum associated with higher ORR in first…”
Get full text

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy by Bradbury, Penelope A., Morris, Donald G., Nicholas, Garth, Tu, Dongsheng, Tehfe, Moustapha, Goffin, John R., Shepherd, Frances A., Gregg, Richard W., Rothenstein, Jeffrey, Lee, Christoper, Kuruvilla, Sara, Keith, Bruce D., Torri, Vamsee, Blais, Normand, Hao, Desiree, Korpanty, Grzegorz J., Goss, Glenwood, Melosky, Barbara L., Mates, Mihaela, Leighl, Natasha, Ayoub, Jean-Pierre, Sederias, Joana, Feilotter, Harriet, Seymour, Lesley, Laurie, Scott A.

“…•Reolysin with chemotherapy did not improve the progression free survival in unselected NSCLC.•A three day regimen of pelareorep was found to be…”
Get full text

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC) by Reck, Martin, Karagiannis, Tom, Wehler, Thomas, Shtivelband, Mikhail, Gonzalez-Larriba, Jose-Luis, Rothenstein, Jeffrey, Frueh, Martin, Deng, Yu, Lopez-Chavez, Ariel, Sandler, Alan, Socinski, Mark A.

“…Abstract only…”
Get full text

Real-world evidence on treatment patterns and survival among ALK+ NSCLC patients in Canada who discontinue crizotinib treatment by Kayaniyil, Sheena, Hurry, Manjusha, Wilson, John, Wheatley-Price, Paul, Melosky, Barbara L., Rothenstein, Jeffrey, Cohen, Victor, Koch, Caroline, Zhang, Jie, Osenenko, Katherine, Liu, Geoffrey

“…Abstract only…”
Get full text

Patients’ willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing by Barnes, Tristan Alexandra, Laskin, Janessa J., Cheema, Parneet Kaur, Liu, Geoffrey, Iqbal, Mussawar, Rothenstein, Jeffrey, Burkes, Ronald L., Owen, Scott Peter, Laurence, David, Carvalhana, Ilda, Markin, Leslie, Wong, Linda, Perera-Low, Nicole, Sawczak, Magdalena, Tsao, Ming-Sound, Leighl, Natasha B.

“…Abstract only e18329 Background: Detection of EGFRmutations in circulating tumor DNA (ctDNA) in peripheral blood has been shown to have high concordance with…”
Get full text

Cloning of transforming growth factor-beta 1 (TGF-beta 1) and its type II receptor from zebrafish ovary and role of TGF-beta 1 in oocyte maturation by Kohli, Gurneet, Hu, Siqin, Clelland, Eric, Di Muccio, Tamara, Rothenstein, Jeffrey, Peng, Chun

“…TGF-beta is a multifunctional factor involved in regulating a variety of cellular activities. In mammals, TGF-beta is known to regulate reproduction, including…”
Get full text

Non-malignant and Tumor-derived Cells Differ in Their Requirement for p27Kip1 in Transforming Growth Factor-β-mediated G1 Arrest by Jeffrey C. H. Donovan, Jeffrey M. Rothenstein, Joyce M. Slingerland

“…Transforming growth factor β (TGF-β) induces G 1 arrest in susceptible cells by multiple mechanisms that inhibit the G 1 cyclin-dependent kinases (Cdks),…”
Get full text